http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015050148-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
filingDate 2014-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab7005cffa25cdd826ba5411089dff18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55b8154d1ff5262fb8149dccbc4c404e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90d9171105eacc1fcac40ddc6c50a2ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6530c0a807209f666826c5fc6df1c152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e0718c29ac01e0fa84e0875147d2ffc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_230184d6a9f18592da53ef6da31c2e3f
publicationDate 2015-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2015050148-A1
titleOfInvention 3-arylpyrazolopyridine derivative
abstract Provided is a compound represented by general formula (I) [where X is a hydrogen atom or a halogen atom, and R is an optionally substituted aryl group or an optionally substituted heteroaryl group], or a pharmaceutically acceptable salt thereof, which has an excellent LCAT activation effect and is useful as the active ingredient of a therapeutic agent or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina, cardiac ischemia, cardiovascular disturbance, and angioplasty-related restenosis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complication), dyslipidemia, hypo-HDL-cholesterolemia, and kidney disease, and particularly as the active ingredient of an antiarteriosclerosis agent.
priorityDate 2013-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008002591-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013187462-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013536807-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S56108712-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID323283053

Total number of triples: 37.